https://www.selleckchem.com/pr....oducts/rimiducid-ap1
r GE ≥6.0mm or male participants were less likely to show complete improvement at 4 weeks. The individual effect of the average dose of BTX-A treatment for GS was GS severity and patient's sex, rather than GS etiology and other individual factors. Further, female participants with baseline anterior GE less then 5.3 mm were more likely to show complete improvement after 4 weeks of this average dose of BTX-A treatment. However, female participants with baseline anterior GE ≥6.0 mm or male participants were less likely to show com
Gefällt mir
Kommentar
Teilen
